Arcus Biosciences (NYSE:RCUS) Stock Rating Upgraded by Wall Street Zen

Arcus Biosciences (NYSE:RCUS) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

Other analysts have also recently issued reports about the stock. Citigroup restated a “buy” rating on shares of Arcus Biosciences in a report on Friday, December 12th. UBS Group reissued a “buy” rating on shares of Arcus Biosciences in a research report on Monday, December 15th. Truist Financial set a $30.00 price target on shares of Arcus Biosciences in a report on Friday, December 12th. Wells Fargo & Company set a $23.00 price target on Arcus Biosciences and gave the stock an “equal weight” rating in a research report on Thursday, February 12th. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $20.00 price objective (down from $23.00) on shares of Arcus Biosciences in a report on Thursday, January 8th. Seven equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Arcus Biosciences has a consensus rating of “Moderate Buy” and an average price target of $29.33.

Arcus Biosciences Trading Up 4.2%

RCUS opened at $20.36 on Friday. The firm has a market cap of $2.55 billion, a price-to-earnings ratio of -6.17 and a beta of 0.85. The company has a current ratio of 4.36, a quick ratio of 4.36 and a debt-to-equity ratio of 0.16. Arcus Biosciences has a 12 month low of $6.50 and a 12 month high of $26.40. The stock has a fifty day moving average price of $21.57 and a 200-day moving average price of $18.56.

Arcus Biosciences (NYSE:RCUS) last issued its quarterly earnings data on Wednesday, February 25th. The company reported ($0.89) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.11) by $0.22. Arcus Biosciences had a negative return on equity of 65.77% and a negative net margin of 142.91%.The company had revenue of $33.00 million for the quarter, compared to the consensus estimate of $24.94 million. During the same quarter last year, the company earned ($1.03) earnings per share. The firm’s revenue for the quarter was down 8.3% compared to the same quarter last year. As a group, equities research analysts anticipate that Arcus Biosciences will post -3.15 earnings per share for the current fiscal year.

Insider Activity at Arcus Biosciences

In other Arcus Biosciences news, CAO Alexander Azoy sold 4,343 shares of the business’s stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $22.25, for a total transaction of $96,631.75. Following the sale, the chief accounting officer owned 18,531 shares in the company, valued at approximately $412,314.75. The trade was a 18.99% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Carolyn C. Tang sold 6,810 shares of the stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $22.16, for a total value of $150,909.60. Following the completion of the transaction, the general counsel directly owned 124,734 shares in the company, valued at $2,764,105.44. This represents a 5.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 263,987 shares of company stock worth $6,025,620 in the last quarter. 9.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Arcus Biosciences

Institutional investors have recently bought and sold shares of the business. T. Rowe Price Investment Management Inc. acquired a new stake in Arcus Biosciences during the 4th quarter valued at approximately $39,000. Invesco Ltd. raised its holdings in shares of Arcus Biosciences by 41.7% during the fourth quarter. Invesco Ltd. now owns 414,365 shares of the company’s stock worth $9,874,000 after purchasing an additional 121,961 shares during the last quarter. State of Tennessee Department of Treasury raised its holdings in shares of Arcus Biosciences by 34.2% during the fourth quarter. State of Tennessee Department of Treasury now owns 34,855 shares of the company’s stock worth $831,000 after purchasing an additional 8,886 shares during the last quarter. VestGen Advisors LLC acquired a new position in Arcus Biosciences during the fourth quarter valued at $647,000. Finally, Wellington Management Group LLP lifted its position in Arcus Biosciences by 309.4% during the fourth quarter. Wellington Management Group LLP now owns 5,184,509 shares of the company’s stock valued at $123,547,000 after purchasing an additional 3,918,220 shares during the period. 92.89% of the stock is owned by hedge funds and other institutional investors.

Arcus Biosciences News Summary

Here are the key news stories impacting Arcus Biosciences this week:

• Positive Sentiment: Analysts’ aggregate view remains constructive — Arcus received an average recommendation of “Moderate Buy” from the analyst community, which supports investor demand. Arcus Receives Average Recommendation
• Positive Sentiment: HC Wainwright raised several near‑term and later‑year estimates (Q1 and Q2 2026 EPS were revised up; FY2028 and FY2029 loss forecasts improved) and reiterated a Buy rating with a $32 price target — that retained Buy conviction can buoy the stock despite mixed cuts elsewhere. MarketBeat RCUS
• Neutral Sentiment: Wall Street Zen upgraded Arcus to a Hold — an incremental change in street coverage that may temper volatility but is not an outright positive endorsement. Arcus Upgraded to Hold
• Neutral Sentiment: Analysts published longer‑range forecasts (FY2030 coverage), adding modelling detail for investors but without an immediate clear directional impact. Analysts Issue FY2030 Forecasts
• Negative Sentiment: Offsetting the positives, HC Wainwright increased loss projections for FY2026 (now -$4.66 vs. prior -$4.00) and raised Q3/Q4 2026 loss estimates — these larger near‑term losses are a negative earnings surprise risk and could weigh on sentiment if cash burn or trial timelines disappoint. HC Wainwright Estimate Changes

Arcus Biosciences Company Profile

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.